Accelerated Corneal Cross-linking With Different Riboflavin Solutions
- Registration Number
- NCT03187912
- Lead Sponsor
- Medical University of Vienna
- Brief Summary
Following the Bunsen-Roscoe law, accelerated cross-linking protocols with higher irradiation intensities and shorter irradiation times have been introduced. In addition, new riboflavin solutions with HPMC (hydroxylpropyl methylcellulose) instead of dextran found its way into CXL-treatment. The aim of this trial is to evaluate clinical outcomes in an accelerated corneal collagen cross-linking protocol with different riboflavin solutions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Progressive Keratoconus
- Indication for treatment
- Preoperative Pachymetry > 400
Read More
Exclusion Criteria
- Pregnancy
- Re-CXL
- Keratitis
- Other visual acuity limiting eye diseases than corneal ectatic diseases
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Riboflavin with HPMC Riboflavin Riboflavin drops with HPMC Riboflavin with 20% Dextran Riboflavin Riboflavin drops with Dextran
- Primary Outcome Measures
Name Time Method Kmax 12 months Steepest Keratometry
- Secondary Outcome Measures
Name Time Method Postoperative central stromal depth of the Demarcation Line 1 month The depth of the Demarcation Line after CXL will be measured one month postoperatively with an AS-OCT
LogMAR 12 months Visual Acuity
Trial Locations
- Locations (1)
Medical University of Vienna, Department of Ophthalmology
🇦🇹Vienna, Austria